| HOME >> BIOLOGY >> TECHNOLOGY |
TORONTO, Feb. 26 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that five abstracts have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008 in San Diego, California. The Company will deliver presentations that will disclose new findings about its CD44, TROP-2, CD59, and CD9 antibody programs.
"The inclusion of five ARIUS abstracts in this conference is a significant achievement, demonstrating the scientific community's interest in our programs and the high quality of our research," said Dr. David Young, President and CEO. "Among these abstracts are findings from our cancer stem cell programs targeting CD44 and CD9. This is an exciting new area of cancer research and as we prepare our CD44 antibody to enter human clinical trials this year, we believe we will have one of the only novel cancer stem cell drugs entering clinical trials in the near-term."
The following ARIUS' abstracts will be presented:
Abstract Number 3975:
"Preclinical development of huARH460-16-2, a humanized antibody to the CD44 cancer stem cell target." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM
Abstract Number 3976:
"Anti-CD44 antibody, ARH460-16-2, binds to human AML CD34+CD38- cancer stem cells and demonstrates anti-tumor activity in an AML xenograft model." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM
Abstract Number 3990:
"AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits anti-tumor efficacy in multiple human cancer models as a monotherapeutic agent and demonstrates efficacy in combination therapy." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM
Abstract Number 3993:
"Anti-CD9 antibody, AR40A746.2.3, inhibits tumor
'/>"/>
| SOURCE ARIUS Research Inc. Copyright©2008 PR Newswire. All rights reserved |